Malaria is one of the most serious infectious diseases in the developing world, with mortality estimated at ca. 2.5 mil- lion deaths annually, mainly caused by the erythrocytic-stage cells of Plasmodium falciparum.1) For four decades, malaria has been treated effectively with the 4-aminoquinoline ana- log chloroquine (CQ). However, CQ-resistant strains of Plas- modium spp. have spread and continue to evolve.1) Therefore, the development of new chemotherapeutic agents ...